.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spreading agent introduced to market

June 15, 2007

San Diego?Baxter Healthcare Corp. has launched its hyaluronidase human injection (Hylenex recombinant) for use in enhancing the absorption and dispersion of injected ophthalmic anesthetics.

San Diego-Baxter Healthcare Corp. has launched its hyaluronidase human injection (Hylenex recombinant) for use in enhancing the absorption and dispersion of injected ophthalmic anesthetics.

The 1-ml single-dose vials contain 150 units of animal-derived hyaluronidase, which is designed to increase the speed of anesthetic onset, enhance its intensity, and decrease the volume of anesthetic required.

The product is a human protein derived from a recombinant source, helping to mitigate concerns about inter-species pathogen transmission and the potential for immunological reactions, the company said. Because it is a recombinant protein, the company expects the supply to be more sustainable than typically associated with animal-derived product, it added.